MedTrace Logo

Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule

NCT01369472 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-02-15

No results posted yet for this study

Summary

This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg, 64mg, 128mg in healthy male volunteers.

Conditions

  • Chronic Stable Angina

Interventions

DRUG

Dilatrend SR capsule

single oral administration in period 1 or 2, 3 for each sequential group.

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • KS Bae, Ph.D · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
54 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01369472 on ClinicalTrials.gov